Lessons from helminth infections: ES-62 highlights new interventional approaches in rheumatoid arthritis

Clinical and Experimental Immunology

Volumn 177, Issue 1, 2014, Pages 13-23

  Pineda, M A ^a   Al Riyami, L ^b   Harnett, W ^b   Harnett, M M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

T cells; ES 62; Helminth immunoregulation; IL 17; Rheumatoid arthritis

Indexed keywords

ALPHA2 INTEGRIN; ANTIRHEUMATIC AGENT; COLLAGEN; ES 62; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; BRUGIA MALAYI; CELL DIFFERENTIATION; DOWN REGULATION; GAMMA DELTA T LYMPHOCYTE; HELMINTHIASIS; IN VIVO STUDY; INNATE IMMUNITY; LOA LOA; NONHUMAN; ONCHOCERCA VOLVULUS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SCHISTOSOMA; TH17 CELL; TRICHURIS SUIS;

ES-62; HELMINTH IMMUNOREGULATION; IL-17; RHEUMATOID ARTHRITIS; ΓΔ T CELLS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; HELMINTH PROTEINS; HELMINTHIASIS; HELMINTHS; HUMANS; HYGIENE HYPOTHESIS; IMMUNOMODULATION; IMMUNOTHERAPY; INTERLEUKIN-17; MICE; TH17 CELLS; THERAPY WITH HELMINTHS;

EID: 84904243945     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12252     Document Type: Article

References (109)

1. McInnes IB, Liew FY. Cytokine networks-towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2005; 1:31-39.
2. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171:6173-6177.
3. Murphy CA, Langrish CL, Chen Y etal. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198:1951-1957.
4. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther 2011; 13:R126.
5. Gullick NJ, Abozaid HS, Jayaraj DM etal. Enhanced and persistent levels of IL-17+CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis. Clin Exp Immunol 2013; 174:292-301.
6. Metawi SA, Abbas D, Kamal MM, Ibrahim MK. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 2011; 30:1201-1207.
7. Cho YG, Cho ML, Min SY, Kim HY. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev 2007; 7:65-70.
8. Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 2011; 13 (Suppl. 1):S4.
9. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxf) 2012; 51 (Suppl. 5):v3-11.
10. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344:907-916.
11. Carroll G, Bell M, Wang H, Chapman H, Mills J. Antagonism of the IL-6 cytokine subfamily-a potential strategy for more effective therapy in rheumatoid arthritis. Inflamm Res 1998; 47:1-7.
12. Papp KA, Langley RG, Sigurgeirsson B etal. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168:412-421.
13. Spuls PI, Hooft L. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol 2012; 167:710-713; discussion 4-5.
14. Papp KA, Leonardi C, Menter A etal. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181-1189.
15. Gandhi M, Alwawi E, Anti GKB. p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 2010; 29:48-52.
16. McInnes IB, Kavanaugh A, Gottlieb AB etal. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780-789.
17. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140-174.
18. Buch MH, Boyle DL, Rosengren S etal. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009; 68:1220-1227.
19. Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 2012; 24:335-341.
20. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013; 72 (Suppl. 2):ii116-123.
21. Nam JL, Winthrop KL, van Vollenhoven RF etal. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69:976-986.
22. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275-2285.
23. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxf) 2012; 51 (Suppl. 6):vi37-43.
24. Pearson DJ, Taylor G. The influence of the nematode Syphacia oblevata on adjuvant arthritis in the rat. Immunology 1975; 29:391-396.
25. Osada Y, Shimizu S, Kumagai T, Yamada S, Kanazawa T. Schistosoma mansoni infection reduces severity of collagen-induced arthritis via down-regulation of pro-inflammatory mediators. Int J Parasitol 2009; 39:457-464.
26. Rocha FA, Leite AK, Pompeu MM etal. Protective effect of an extract from Ascaris suum in experimental arthritis models. Infect Immun 2008; 76:2736-2745.
27. Shi M, Wang A, Prescott D etal. Infection with an intestinal helminth parasite reduces Freund's complete adjuvant-induced monoarthritis in mice. Arthritis Rheum 2011; 63:434-444.
28. Rooney BK, Silman AJ. Epidemiology of the rheumatic diseases. Curr Opin Rheumatol 1999; 11:91-97.
29. Silman AJ, Ollier W, Holligan S etal. Absence of rheumatoid arthritis in a rural Nigerian population. J Rheumatol 1993; 20:618-622.
30. Fleming JO, Cook TD. Multiple sclerosis and the hygiene hypothesis. Neurology 2006; 67:2085-2086.
31. Hagel I, Lynch NR, Perez M, Di Prisco MC, Lopez R, Rojas E. Modulation of the allergic reactivity of slum children by helminthic infection. Parasite Immunol 1993; 15:311-315.
32. Araujo MI, Lopes AA, Medeiros M etal. Inverse association between skin response to aeroallergens and Schistosoma mansoni infection. Int Arch Allergy Immunol 2000; 123:145-148.
33. Cooke A. Review series on helminths, immune modulation and the hygiene hypothesis: how might infection modulate the onset of type 1 diabetes? Immunology 2009; 126:12-17.
34. Panda AK, Ravindran B, Das BK. Rheumatoid arthritis patients are free of filarial infection in an area where filariasis is endemic: comment on the article by Pineda etal. Arthritis Rheum 2013; 65:1402-1403.
35. Subramanian S, Stolk WA, Ramaiah KD etal. The dynamics of Wuchereria bancrofti infection: a model-based analysis of longitudinal data from Pondicherry, India. Parasitology 2004; 128:467-482.
36. Allen JE, Maizels RM. Diversity and dialogue in immunity to helminths. Nat Rev Immunol 2011; 11:375-388.
37. Rook GA. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: darwinian medicine and the 'hygiene' or 'old friends' hypothesis. Clin Exp Immunol 2010; 160:70-79.
38. Stoll NR. This wormy world. J Parasitol 1947; 33:1-18.
39. Craig P, Ito A. Intestinal cestodes. Curr Opin Infect Dis 2007; 20:524-532.
40. Pawlowski Z. Global health situation with emphasis on selected parasitic infections in Poland. Wiad Parazytol 2008; 54:17-22.
41. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299:1259-1260.
42. Yazdanbakhsh M, van den Biggelaar A, Maizels RM. Th2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic disease. Trends Immunol 2001; 22:372-377.
43. Rook GA. Hygiene hypothesis and autoimmune diseases. Clin Rev Allergy Immunol 2012; 42:5-15.
44. Okada H, Kuhn C, Feillet H, Bach JF. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol 2010; 160:1-9.
45. Khan WI, Blennerhasset PA, Varghese AK etal. Intestinal nematode infection ameliorates experimental colitis in mice. Infect Immun 2002; 70:5931-5937.
46. Sewell D, Qing Z, Reinke E etal. Immunomodulation of experimental autoimmune encephalomyelitis by helminth OVA immunization. Int Immunol 2003; 15:59-69.
47. La Flamme AC, Canagasabey K, Harvie M, Backstrom BT. Schistosomiasis protects against multiple sclerosis. Mem Inst Oswaldo Cruz 2004; 99 (5 Suppl. 1):33-36.
48. Saunders KA, Raine T, Cooke A, Lawrence CE. Inhibition of autoimmune type 1 diabetes by gastrointestinal helminth infection. Infect Immun 2007; 75:397-407.
49. Wilson MS, Taylor MD, Balic A, Finney CA, Lamb JR, Maizels RM. Suppression of allergic airway inflammation by helminth-induced regulatory T cells. J Exp Med 2005; 202:1199-1212.
50. Osada Y, Kanazawa T. Parasitic helminths: new weapons against immunological disorders. J Biomed Biotechnol 2010; 2010:743758.
51. Jouvin MH, Kinet JP. Trichuris suis ova: testing a helminth-based therapy as an extension of the hygiene hypothesis. J Allergy Clin Immunol 2012; 130:3-10; quiz 1-2.
52. Fleming JO. Helminth therapy and multiple sclerosis. Int J Parasitol 2013; 43:259-274.
53. Harn DA, McDonald J, Atochina O, Da'dara AA. Modulation of host immune responses by helminth glycans. Immunol Rev 2009; 230:247-257.
54. Bhargava P, Li C, Stanya KJ etal. Immunomodulatory glycan LNFPIII alleviates hepatosteatosis and insulin resistance through direct and indirect control of metabolic pathways. Nat Med 2012; 18:1665-1672.
55. Dutta P, Hullett DA, Roenneburg DA etal. Lacto-N-fucopentaose III, a pentasaccharide, prolongs heart transplant survival. Transplantation 2010; 90:1071-1078.
56. Everts B, Perona-Wright G, Smits HH etal. Omega-1, a glycoprotein secreted by Schistosoma mansoni eggs, drives Th2 responses. J Exp Med 2009; 206:1673-1680.
57. Everts B, Hussaarts L, Driessen NN etal. Schistosome-derived omega-1 drives Th2 polarization by suppressing protein synthesis following internalization by the mannose receptor. J Exp Med 2012; 209:1753-1767. S1.
58. van der Kleij D, Latz E, Brouwers JF etal. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates Toll-like receptor 2 and affects immune polarization. J Biol Chem 2002; 277:48122-48129.
59. Taylor MJ, Bandi C, Hoerauf A. Wolbachia bacterial endosymbionts of filarial nematodes. Adv Parasitol 2005; 60:245-284.
60. Harnett W, Harnett MM, Byron O. Structural/functional aspects of ES-62-a secreted immunomodulatory phosphorylcholine-containing filarial nematode glycoprotein. Curr Protein Pept Sci 2003; 4:59-71.
61. Harnett W, Houston KM, Tate R etal. Molecular cloning and demonstration of an aminopeptidase activity in a filarial nematode glycoprotein. Mol Biochem Parasitol 1999; 104:11-23.
62. Houston KM, Wilson EH, Eyres L etal. Presence of phosphorylcholine on a filarial nematode protein influences immunoglobulin G subclass response to the molecule by an interleukin-10-dependent mechanism. Infect Immun 2000; 68:5466-5468.
63. Deehan MR, Frame MJ, Parkhouse RM etal. A phosphorylcholine-containing filarial nematode-secreted product disrupts B lymphocyte activation by targeting key proliferative signaling pathways. J Immunol 1998; 160:2692-2699.
64. Goodridge HS, Wilson EH, Harnett W, Campbell CC, Harnett MM, Liew FY. Modulation of macrophage cytokine production by ES-62, a secreted product of the filarial nematode Acanthocheilonema viteae. J Immunol 2001; 167:940-945.
65. Harnett MM, Deehan MR, Williams DM, Harnett W. Induction of signalling anergy via the T-cell receptor in cultured Jurkat T cells by pre-exposure to a filarial nematode secreted product. Parasite Immunol 1998; 20:551-563.
66. Marshall FA, Grierson AM, Garside P, Harnett W, Harnett MM. ES-62, an immunomodulator secreted by filarial nematodes, suppresses clonal expansion and modifies effector function of heterologous antigen-specific T cells in vivo. J Immunol 2005; 175:5817-5826.
67. Marshall FA, Watson KA, Garside P, Harnett MM, Harnett W. Effect of activated antigen-specific B cells on ES-62-mediated modulation of effector function of heterologous antigen-specific T cells in vivo. Immunology 2008; 123:411-425.
68. Whelan M, Harnett MM, Houston KM, Patel V, Harnett W, Rigley KP. A filarial nematode-secreted product signals dendritic cells to acquire a phenotype that drives development of Th2 cells. J Immunol 2000; 164:6453-6460.
69. Pineda MA, McGrath MA, Smith PC etal. The parasitic helminth product ES-62 suppresses pathogenesis in collagen-induced arthritis by targeting the interleukin-17-producing cellular network at multiple sites. Arthritis Rheum 2012; 64:3168-3178.
70. Goodridge HS, Harnett W, Liew FY, Harnett MM. Differential regulation of interleukin-12 p40 and p35 induction via Erk mitogen-activated protein kinase-dependent and -independent mechanisms and the implications for bioactive IL-12 and IL-23 responses. Immunology 2003; 109:415-425.
71. Goodridge HS, Marshall FA, Else KJ etal. Immunomodulation via novel use of TLR4 by the filarial nematode phosphorylcholine-containing secreted product, ES-62. J Immunol 2005; 174:284-293.
72. Poltorak A, He X, Smirnova I etal. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 1998; 282:2085-2088.
73. Harnett W, Goodridge HS, Allen JM, Harnett M. Receptor usage by the Acanthocheilonema viteae-derived immunomodulator, ES-62. Exp Parasitol 2012; 132:97-102.
74. Goodridge HS, McGuiness S, Houston KM etal. Phosphorylcholine mimics the effects of ES-62 on macrophages and dendritic cells. Parasite Immunol 2007; 29:127-137.
75. Hepworth MR, Maurer M, Hartmann S. Regulation of type 2 immunity to helminths by mast cells. Gut Microbes 2012; 3:476-481.
76. Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol 2011; 12:1035-1044.
77. Moon TC, St Laurent CD, Morris KE etal. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol 2010; 3:111-128.
78. Melendez AJ, Harnett MM, Pushparaj PN etal. Inhibition of Fc epsilon RI-mediated mast cell responses by ES-62, a product of parasitic filarial nematodes. Nat Med 2007; 13:1375-1381.
79. Ball DH, Tay HK, Bell KS etal. Mast cell subsets and their functional modulation by the Acanthocheilonema viteae product ES-62. J Parasitol Res 2013; 2013:961268.
80. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9:293-307.
81. Fung I, Garrett JP, Shahane A, Kwan M. Do bugs control our fate? The influence of the microbiome on autoimmunity. Curr Allergy Asthma Rep 2012; 12:511-519.
82. McInnes IB, Leung BP, Harnett M, Gracie JA, Liew FY, Harnett W. A novel therapeutic approach targeting articular inflammation using the filarial nematode-derived phosphorylcholine-containing glycoprotein ES-62. J Immunol 2003; 171:2127-2133.
83. Harnett MM, Kean DE, Boitelle A etal. The phosphorycholine moiety of the filarial nematode immunomodulator ES-62 is responsible for its anti-inflammatory action in arthritis. Ann Rheum Dis 2008; 67:518-523.
84. Houston KM, Sutharsan R, Steiger CN, Schachter H, Harnett W. Gene inactivation confirms the identity of enzymes involved in nematode phosphorylcholine-N-glycan synthesis. Mol Biochem Parasitol 2008; 157:88-91.
85. Hewitson JP, Harcus YM, Curwen RS etal. The secretome of the filarial parasite, Brugia malayi: proteomic profile of adult excretory-secretory products. Mol Biochem Parasitol 2008; 160:8-21.
86. Kellner H. Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskelet Dis 2013; 5:141-152.
87. Genovese MC, Van den Bosch F, Roberson SA etal. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62:929-939.
88. Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum 2011; 63:622-632.
89. Dick AD, Tugal-Tutkun I, Foster S etal. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013; 120:777-787.
90. Kisand K, Boe Wolff AS, Podkrajsek KT etal. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010; 207:299-308.
91. Hueber W, Sands BE, Lewitzky S etal. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61:1693-1700.
92. Yoshiga Y, Goto D, Segawa S etal. Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis. Int J Mol Med 2008; 22:369-374.
93. Ito Y, Usui T, Kobayashi S etal. Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum 2009; 60:2294-2303.
94. Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009; 31:321-330.
95. Grajewski RS, Hansen AM, Agarwal RK etal. Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. J Immunol 2008; 181:4791-4797.
96. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009; 31:331-341.
97. Doisne JM, Becourt C, Amniai L etal. Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor (gamma)t+ and respond preferentially under inflammatory conditions. J Immunol 2009; 183:2142-2149.
98. Haas JD, Gonzalez FH, Schmitz S etal. CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells. Eur J Immunol 2009; 39:3488-3497.
99. Shibata K, Yamada H, Nakamura R, Sun X, Itsumi M, Yoshikai Y. Identification of CD25+ gamma delta T cells as fetal thymus-derived naturally occurring IL-17 producers. J Immunol 2008; 181:5940-5947.
100. Mielke LA, Jones SA, Raverdeau M etal. Retinoic acid expression associates with enhanced IL-22 production by gammadelta T cells and innate lymphoid cells and attenuation of intestinal inflammation. J Exp Med 2013; 210:1117-1124.
101. Simonian PL, Wehrmann F, Roark CL, Born WK, O'Brien RL, Fontenot A. P. gammadelta T cells protect against lung fibrosis via IL-22. J Exp Med 2010; 207:2239-2253.
102. Ke Y, Liu K, Huang GQ etal. Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol 2009; 182:3183-3190.
103. Sonnenberg GF, Nair MG, Kirn TJ, Zaph C, Fouser LA, Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010; 207:1293-1305.
104. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27:647-659.
105. Geboes L, Dumoutier L, Kelchtermans H etal. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum 2009; 60:390-395.
106. Kelchtermans H, Schurgers E, Geboes L etal. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res Ther 2009; 11:R122.
107. Fleming J, Isaak A, Lee J etal. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult Scler 2011; 17:743-754.
108. Bager P, Kapel C, Roepstorff A etal. Symptoms after ingestion of pig whipworm Trichuris suis eggs in a randomized placebo-controlled double-blind clinical trial. PLOS ONE 2013; 6:e22346.
109. Al-Riyami L, Pineda MA, Rzepecka J etal. Designing anti-inflammatory drugs from parasitic worms: a synthetic small molecule analogue of the Acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis. J Med Chem 2013; 56:9982-10002.